H eart failure (HF) with preserved ejection fraction (HFpEF) was recognized as a separate entity from systolic HF or HF with reduced ejection fraction >30 years ago. 1 However, it continues to be one of the largest unmet needs in cardiovascular medicine. 2 During the past 5 to 10 years, many advances have been made in the understanding of HFpEF pathogenesis, including abnormalities in diastolic function, arterial stiffness, ventricular-arterial coupling, endothelial function, and chronotropic incompetence, among others. [3] [4] [5] Despite these advances, HFpEF remains a clinical syndrome without effective preventive or therapeutic options, as all randomized clinical trials in the field have yielded neutral or negative results to date. Reduced MFR in HFpEF accurately quantifying myocardial flow reserve (MFR), the ratio of myocardial blood flow (MBF) at peak stress to MBF at rest, which in turn represents the vasodilatory reserve of the coronary circulation. In patients without significant epicardial disease, MFR can be considered a marker of microvascular function and a surrogate for coronary vascular health. 9, 10 In addition, MFR has been shown to have prognostic value in patients with suspected epicardial coronary artery disease (CAD), 11 and in the absence of CAD, changes in MFR reflect alterations in coronary microvascular function.
Given the gaps in knowledge about potential in vivo abnormalities in coronary microvascular function in patients with HFpEF, this study was designed to evaluate MFR in HFpEF patients undergoing clinically indicated cardiac PET imaging, in the absence of significant epicardial CAD. We hypothesized that MFR would be reduced in HFpEF patients compared with controls without HF, representing microvascular dysfunction.
Methods Study Design and Patients
A retrospective database review of quantitative MBF and MFR in patients referred for cardiac PET at the University of Ottawa Heart Institute between May 2010 and September 2013 was conducted. The final sample size was determined after 3 levels of screening to identify patients with HFpEF and controls ( Figure I in the Data Supplement). At the first level, subjects undergoing clinically indicated PET who had data available for quantification of MFR, with ejection fraction ≥50% and summed stress score <4 (suggestive of low likelihood of obstructive epicardial CAD) [11] [12] [13] were considered eligible for further screening (1169 subjects). At the second level of screening, subjects were further subdivided into controls, based on absence of HF or dyspnea (n=405) and those with possible HF (n=764), based on New York Heart Association (NYHA) symptom classification ≥1. The third level of screening involved the adjudication of a diagnosis of HFpEF by detailed review of medical records. Of note, no stringent criteria were used to identify and exclude those patients in the study with significant left-sided valvular heart disease or infiltrative cardiomyopathy. A final diagnosis of HFpEF was established when all 3 criteria were met: (1) NYHA ≥1 class symptoms, (2) left ventricle ejection fraction ≥50% at the time of PET evaluation, and (3) confirmed diagnosis of HFpEF from medical records. This included any of a consultant diagnosis or a visit or admission to hospital for HF. The presence of clinical HF was adjudicated by a reviewer blinded to imaging data. Any subject with evidence of epicardial CAD was excluded from the study. This included any of (1) abnormal perfusion summed stress score (SSS ≥4), (2) documented history of myocardial infarction, angina, acute coronary syndrome, or myocardial revascularization from review of the medical records, (3) coronary angiography or computed tomography angiography demonstrating a significant degree of coronary artery obstruction (≥70% luminal obstruction), the latter of which was available in ≈12% of those designated as having HFpEF. Because hypertension is the most prevalent comorbidity among HFpEF patients, controls were subdivided into hypertensive and normotensive based on self-reporting at the time of PET scan. After this detailed review, a total of 78 HFpEF subjects and 298 non-HF controls (112 normotensive and 186 hypertensive) were included in the study. The study was approved by the University of Ottawa Heart Institute's Research Ethics Board, and study subjects provided informed consent.
PET Imaging Protocol
Rb-82 PET imaging protocol has been described previously. 14, 15 In short, patients were positioned in a Discovery 690 or RX PET-CT system (GE Healthcare, Waukesha, WI). After a low-dose computed tomography scan acquired for attenuation correction, 14, 15 10 MBq/kg of Rb-82 was administered intravenously as a 30-second square-wave using a feedback-controlled elution system (Jubilant DraxImage, Montreal, QC). Dynamic Rb-82 PET images were acquired during 10 minutes using a list-mode acquisition. After the rest PET acquisition, dipyridamole (0.14 mg/kg/min for 5 minutes) was administered to induce vasodilation for stress imaging. Rb-82 infusion was initiated at the 3-minutes mark after completion of the dipyridamole infusion. Dynamic images were acquired as per rest imaging. A low-dose computed tomography scan was repeated after stress imaging for attenuation correction.
Dynamic, static, and gated images were reconstructed using the vendor iterative algorithm (VuePoint HD) with 8, 12, and 16 mm Hann postfilter, respectively, as previously described.
14,15

Image Interpretation
Semi-quantitative perfusion analysis was based on the static images, performed by nuclear cardiology experts blinded to clinical data. A standard 17-segment (5-point) model was used to score the extent and severity of relative perfusion defects in the whole heart and also divided into left anterior descending artery, left circumflex artery, and right coronary artery territories. The summed stress score, summed rest score, and summed difference score were calculated. Corridor-4DM software (INVIA, Ann Arbor, MI) was used to determine left ventricle ejection fraction during rest and peak stress.
Automated FlowQuant software (Ottawa, Ontario, Canada) was used to reorientate images and define myocardial and left ventricle cavity time-activity curves. Polar maps of absolute MBF at rest and poststress were generated. MFR was calculated as the ratio of the stress/rest MBF 11, 15, 16 ( Figure II in the Data Supplement for sample Rubidium-82 PET myocardial perfusion and flow quantification images in a 57-year-old female patient with HFpEF).
Echocardiographic Analysis
To determine the relationship between MFR and echocardiographic parameters of diastolic dysfunction in this study cohort, we identified subjects with transthoracic 2D and Doppler echocardiogram performed within 6 months of the PET scan. Subjects with mitral stenosis, severe mitral regurgitation, or severe mitral annular calcification were excluded from these analyses, because these conditions make diastolic assessment inaccurate. A total of 115 subjects were eligible and included in the echocardiographic analysis. The detailed methodology and results can be found in the Data Supplement.
Statistical Analyses
Mean and SD were calculated for continuous variables, whereas frequencies and percentages were determined for categorical variables. Continuous variables were compared between HFpEF subjects, normotensive controls, and hypertensive controls using one-way ANOVA with post hoc Tukey procedure to determine the significance of pairwise comparisons, whereas categorical variables were compared using χ 2 test. Pearson correlation coefficients were used to assess the relationship of left ventricular mass and echocardiographic parameters of diastolic function with MFR.
To determine whether the presence of HFpEF was an independent predictor of lower global and regional MFR, we performed multivariable linear regression analyses using global MFR, left anterior descending artery MFR, left circumflex artery, MFR, and right coronary artery MFR (in separate models) as dependent variables and presence of HFpEF as an independent variable. In addition, multivariate logistic regression was used to identify significant predictors of a low global MFR, which was defined as <2 on the basis of previous studies suggesting lower normal limits between 2 and 2.5. 10, 17 Models were adjusted for the following parameters: age, sex, body mass index, mean arterial pressure, heart rate, and history of hypertension, diabetes mellitus, dyslipidemia, statin use, atrial fibrillation, and smoking. All analyses were performed using IBM SPSS statistic software (versions 22-23), and statistical significance was defined as P≤0.05 (2 sided). Table 1 shows the characteristics of subjects included in the study. The vast majority of these patients were referred for chest pain (≈50%). The remaining patients were referred for dyspnea (35% of those with HFpEF), preoperative assessment (mostly prebariatric surgery in those with cardiac risk factors), arrhythmia, and other nonclassic indications, such as abnormal screening exercise stress test, methoxy-isobutyl-isonitrile scan, or ECG in asymptomatic patients. The mean age was 63±11 years, and 63% were women, of whom 66% were post menopausal. Approximately 85% of those in the HFpEF group had NYHA class 1 to 2 symptoms with the remaining 13% and 2% falling into NHYA classes 3 and 4, respectively. The prevalence of hypertension was higher in the HFpEF cohort when compared with the non-HF control group (78% versus 62%; P=0.006). Patients with HFpEF were also more likely to be older, female, and have renal dysfunction, dyslipidemia, diabetes mellitus, atrial fibrillation, relative obesity, and anemia when compared with normotensive controls. Medication use reported at the time of PET scan is shown in Table 1 . There was a greater use of antihypertensive medications, diuretics, antiplatelet agents, anticoagulant, and insulin in the HFpEF group compared with controls, which is not surprising given the relatively higher prevalence of comorbid hypertension, atrial fibrillation, and diabetes mellitus in this group. Table 2 outlines baseline PET parameters of subjects included in the study (please also refer to Table I in the Data Supplement containing baseline echocardiographic parameters of the study subjects). There was no statistical difference between the summed stress score of HFpEF compared with controls (hypertensive or normotensive; P=0.466). In fact, more than three fourth of patients in either group had a summed stress score of 0. No statistical difference was seen between mean heart rate and mean arterial pressure (rest or stress) documented at the time of the PET scan. Resting MBF was significantly greater in the HFpEF group compared with normotensive controls. The resting rate pressure product was also significantly higher in HFpEF compared with normotensive controls. Importantly, stress MBF, on the contrary, was significantly lower in the HFpEF group compared with that in the normotensive controls. These values in the hypertensive control group were not significantly different from either the HFpEF or normotensive controls, albeit a trend toward significance was noted in stress MBF in hypertensive versus normotensive controls.
Results
Baseline Characteristics of HFpEF Versus Non-HF Controls
MFR in HFpEF Versus Non-HF Controls
HFpEF was associated with lower global and regional MFR than non-HF controls (Table 3 ). The mean global MFR was 2.16±0.69 in HFpEF, which was significantly lower compared with 2.54±0.80 (P=0.001) in hypertensive controls and 2.89±0.70 (P<0.001) in normotensive controls. When data were further stratified on the basis of NYHA class subgroups (no dyspnea or control group versus classes 1-2 versus 3-4), MFR decreased as HF severity increased ( Table 3 ). The mean global MFR was 2.67±0.78 in non-HF controls, 2.21±0.71 (P<0.001) in HFpEF subjects with NYHA class 1-2 symptoms, and 1.88±0.53 (P<0.005) in HFpEF subjects with NYHA class 3-4 symptoms. The presence of HFpEF was significantly associated with reduced global MFR independently of potential confounders including age, sex, and history of hypertension and diabetes mellitus ( Table 4) . The results of logistic regression analyses to determine the effect of HFpEF and other covariates on the presence of low global MFR (<2.0) revealed that HFpEF was associated with an unadjusted 2.62 times greater odds (P<0.001) of having a global MFR <2.0. After adjustment for summed stress score, rest and stress HR, mean arterial pressure, age, sex, and history of smoking, diabetes mellitus, dyslipidemia, hypertension, atrial fibrillation, and statin use, the odds of having a global MFR <2.0 was 1.40 (P=0.279) for patients with HFpEF.
The global and regional MFR was also determined for the 628 patients excluded from the HFpEF group on the basis of Table 3 ).
Baseline echocardiographic data and analysis of global and regional MFR in those with identified echocardiographic evidence of diastolic dysfunction can be found in Table I in the  Data Supplement and Table 5 , respectively. When MFR was compared between those with any level of diastolic dysfunction (grades 1-4, regardless of the presence of HF) and normal diastolic function, a significant reduction was noted in the former (global MFR 2.03±0.55 in those with any degree of diastolic dysfunction versus 2.83±0.69 with no diastolic dysfunction; P<0.001; Table 5 ). Please refer to the Data Supplement for full details on echocardiographic methodology and results.
Discussion
This study demonstrated reduced MFR in patients with a diagnosis of HFpEF when compared with hypertensive and Values are represented as mean±SD or n (%). HFpEF indicates heart failure with preserved ejection fraction; HR, heart rate; LVEF, left ventricle ejection fraction; MAP, mean arterial pressure; MBF, myocardial blood flow; MFR, myocardial flow reserve; PET, positron emission tomography; and SSS, summed stress score.
*P value comparing HFpEF to normotensive controls (post hoc Tukey test). †P value comparing HFpEF to hypertensive controls (post hoc Tukey test).
‡P value comparing HFpEF, normotensive controls, and hypertensive controls in χ 2 analysis. §P value comparing hypertensive to normotensive controls (post hoc Tukey test). Reduced MFR in HFpEF normotensive controls in the absence of a known history of obstructive epicardial CAD. The relationship of reduced MFR to presence of HFpEF was independent of age, sex, hypertension, smoking status, diabetes mellitus, dyslipidemia, body mass index, statin use, baseline angina history, and presence of atrial fibrillation. To the best of our knowledge, this is the first report of (1) cardiac PET demonstrating abnormal MFR in individuals with HFpEF and (2) inferred in vivo coronary microvascular dysfunction in a large sample of individuals with HFpEF with no known history of obstructive CAD. These results contribute toward a better understanding of the pathogenic processes predisposing to HFpEF, an important step in the development of novel diagnostic, preventative, and therapeutic strategies for this condition.
Mechanistically, 2 potential explanations for impaired MFR in HFpEF include (1) abnormal microvascular function and (2) an absolute decrease in the number of resistance vessels of the microcirculation. Systemic and local vascular responses to exercise have been demonstrated to be abnormal in HFpEF patients, implicating microvascular dysfunction in this group. 4, 18 In addition, an autopsy study by Mohammed et al 7 on those with antemortem diagnosis of HFpEF showed a greater prevalence of microscopic hypertrophy and fibrosis in this group. This study found lower coronary microvascular density in those with HFpEF and an inverse relationship between microvascular density and myocardial fibrosis. Thus, reduced MFR may promote the development of the HFpEF syndrome through the development of fibrosis and hypertrophy. A review by Paulus and Tschöpe 6 further supports this view by proposing that coronary artery microvascular inflammation and dysfunction as a downstream consequence of a proinflammatory cascade leads to hypertrophy and myocyte stiffening, resulting in HFpEF. After this, van Empel et al 8 showed that measured exercise transcardiac oxygen gradient was significantly lower in HFpEF patients compared with healthy and hypertensive controls, suggesting impaired myocardial oxygen delivery (presumably because of microvascular dysfunction, although epicardial coronary arteries were not assessed) in this group. To further validate this possibility, we proposed examining MFR in a cohort of patients who had undergone clinically indicated PET scans at our institution. MFR has been studied as a surrogate for coronary vascular health. In fact, MFR has been shown to have prognostic value in those with hypertrophic cardiomyopathy, cardiac transplantation, and suspected epicardial CAD. 11, 15, 19 Cardiac PET evaluation of patients with hypertrophic cardiomyopathy demonstrated that reduced MFR was a significant predictor of systolic dysfunction and increased end-diastolic left ventricle dimensions, identifying the prognostic importance of reduced MFR and progressive HF in these patients. 19 McArdle et al 15 showed that MFR was a significant predictor of a composite of all-cause death, acute coronary syndrome, and hospitalization for HF in those ≥12 months postcardiac transplantation. Similarly, Ziadi et al 11 demonstrated that low MFR (<2.0) was a significant predictor of hard events (cardiac death and myocardial infarction) and major adverse cardiac events (cardiac death, myocardial infarction, late revascularization, and cardiac hospitalization) in those being evaluated for cardiac 20 showed that in all patients referred for cardiac PET imaging with suspected or known CAD, MFR values in the lowest tertile (MFR <1.5) were associated with higher 3-year cardiac mortality and risk of cardiac death compared with those with MFR in the highest tertile (MFR >2). Global MFR has also been studied in patients with renal insufficiency and was noted to be impaired in this population despite normal regional perfusion and left ventricle function. 21 To our knowledge, this is the first study to demonstrate reduced MFR using PET imaging in patients with HFpEF, extending and supporting recent work in this area. In this study, we showed that MFR was significantly lower in HFpEF than in controls, and more pronounced in HFpEF subjects with severe symptomatic HF (NYHA functional class 3-4). The presence of HFpEF was a strong independent predictor of global MFR. In addition, global MFR was significantly reduced in the presence of echocardiographic evidence of diastolic dysfunction. Whether reduced MFR has a causal or consequential role in the severity of diastolic dysfunction cannot be determined from this study. A diagnosis of HFpEF was associated with an unadjusted 2.62 times increased odds of having reduced global MFR (defined as <2.0). The loss of significance in odds after adjustment for variables, such as age, sex, hypertension, and diabetes mellitus, may be because of statistical power and sample size or possibly reflect other unidentified confounders affecting the relationship between MFR and HFpEF. Previous studies have demonstrated that MFR <2.0 is associated with a significant increase in the risk of cardiac events and death. 11, 21, 22 In addition to adding pathophysiologic insight into associations of HFpEF, the results of this study justify further research to determine if MFR may represent a novel prognostic risk factor for patients with HFpEF.
There was a stepwise decrease in MFR when comparing normotensive controls to hypertensive controls to patients with HFpEF. This finding is consistent with recent work by our group demonstrating a relationship between reduced MFR and higher pulsatile arterial load in older hypertensive women, who are at highest risk for HFpEF (T. Coutinho, et al, unpublished data, 2016) . Thus, hypertension and hemodynamic load may adversely affect the coronary microvasculature, a mechanism that could predispose to HFpEF. Taken together, these results support the role for microvascular dysfunction in the pathophysiology of HFpEF.
Resting MBF was significantly higher in HFpEF compared with normotensive controls. This likely reflects increased resting metabolic demand, as supported by the significantly higher resting rate pressure product. It is unlikely that resting flow values alone explain the reduced MFR in HFpEF. This is supported by the observation that the percentage difference in mean global flow MFR for HFpEF versus normotensive controls is greater than the percentage difference between rest flow in these groups. More importantly, stress flow is significantly reduced in HFpEF compared with normotensive controls. Blunted vasodilator response of coronary microvascular bed to acetylcholine in HFpEF as a result of coronary microvascular endothelial inflammation has been previously described 6 and can account for the lower stress MBF noted in this group.
There are currently no therapies to directly and selectively target patients with HFpEF. Large clinical trials examining the role of various therapeutic agents, such as β-blockers, [23] [24] [25] [26] angiotensin receptor blockers, 27, 28 aldosterone antagonists, 29, 30 digoxin, 31 and phosphodiesterase type 5 inhibitors, 32 in HFpEF have yielded neutral or negative results. Some trials have shown a trend toward benefit including less HF hospital admissions in Candestartan in Hart Failure: Assessment of Mortality and Morbidity (CHARM)-preserved and Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT). 27, 30 The Prospective Comparison of ARNI With ARB on the Management of Heart Failure with Preserved Ejection Fraction (PARAMOUNT) trial showed a reduction in N terminal prohormone of brain natriuretic peptide-brain natriuretic peptide with use of LCZ696, a first-in-class angiotensin receptor-neprilysin inhibitor; however, its clinical effects are currently under study. 33 Studies that examined the benefit of statin therapy in HFpEF have been equivocal. 34, 35 This study also shows that there was no difference in MFR in patients with or without background statin use. Whether there is a role for statin therapy introduced early in the course of HFpEF, the optimal dose, and compliance were not addressed in this study. At present, the mainstay long-term treatment of HFpEF remains aggressive risk factor modification and diuresis in decompensated patients. Given the lack of HFpEF therapeutic options, deeper understanding of its pathophysiology is needed to control this syndrome and improve outcomes. Our study shows that HFpEF is associated with abnormal MFR, a surrogate of microvascular dysfunction. Whether this represents a potential novel prognostic marker or can serve as a novel therapeutic target in HFpEF needs to be elucidated in further mechanistic and prospective studies. HFpEF indicates heart failure with preserved ejection fraction; HR, heart rate; MAP, mean arterial pressure; MFR, myocardial flow reserve; and SSS, summed stress score. Reduced MFR in HFpEF
Study Limitations
The main limitation of this study includes the single-center, cross-sectional, and retrospective design (which limits us from making inferences on the causality and temporality of the associations noted herein). However, it provides a novel description and foundation on which to base future prospective studies. In addition, the diagnosis of HFpEF and CAD was dependent on the adequacy and availability of medical records. Objective measures such as echocardiographic data at time of study inclusion and BNP values may have offered more robust enrollment criteria. Despite this, the MFR of the 628 patients excluded from the study, with no documented evidence of HFpEF diagnosis despite having an NYHA classification ≥1, was similar to the control group and significantly greater than the HFpEF cohort. In addition, the MFR was similar in HFpEF patients regardless of whether CAD was excluded from evidence of angiography (available in only 12% of subjects) or medical records. Echocardiographic data were available in ≈54% of HFpEF subjects within 6 months of initial PET scan, and the observed relationships between echocardiographic assessment of diastolic function and diagnosis of HFpEF support the classification schema used in this study. This study included a referral population, presumably with greater burden of comorbidities, and thus, referral bias cannot be excluded. In addition, many subjects in this study were referred for symptoms of angina, and this may not reflect a cohort of HFpEF patients not referred for a PET study. However, the prevalence of cardiovascular comorbidities such as hypertension, diabetes mellitus, and dyslipidemia was comparable to that seen in similarly aged adults from the general population, 36 improving the generalizability of our findings. Finally, the findings are limited by the lack of reported outcome data; however, these results confirm and extend previous work in this area and justify further prospective, outcome-based studies.
Conclusions
Microvascular dysfunction, represented here by reduced MFR, is present in HFpEF and may serve as a diagnostic, screening, or therapeutic target in this population. Longitudinal studies are needed to clarify the prognostic role of MFR in HFpEF. To this end, quantification of blood flow using PET may serve as a beneficial tool for risk stratification and prognostication in this population and may add further insight into the pathophysiology of this disease. 
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